PRTK Key Statistics, Chart & Performance
The current stock price of PRTK is 2.23 USD. In the past month the price increased by 2.29%. In the past year, price decreased by -2.62%.
PRTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.1 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.51B | ||
| MRK | MERCK & CO. INC. | 12.04 | 263.24B | ||
| PFE | PFIZER INC | 7.81 | 142.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.26 | 110.36B | ||
| ZTS | ZOETIS INC | 19.94 | 55.71B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.49 | 22.51B | ||
| VTRS | VIATRIS INC | 5.38 | 14.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.71 | 11.31B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.77 | 7.38B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.61B |
Related stock screener links
About PRTK
Company Profile
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 268 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. The company markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Company Info
PARATEK PHARMACEUTICALS INC
75 Park Plaza, 4th Floor
Boston MASSACHUSETTS 02116 US
CEO: Evan Loh
Employees: 268
Phone: 16178076600.0
PARATEK PHARMACEUTICALS INC / PRTK FAQ
What does PARATEK PHARMACEUTICALS INC do?
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 268 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. The company markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Can you provide the latest stock price for PARATEK PHARMACEUTICALS INC?
The current stock price of PRTK is 2.23 USD. The price increased by 1.83% in the last trading session.
Does PRTK stock pay dividends?
PRTK does not pay a dividend.
How is the ChartMill rating for PARATEK PHARMACEUTICALS INC?
PRTK has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of PRTK stock?
PARATEK PHARMACEUTICALS INC (PRTK) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of PARATEK PHARMACEUTICALS INC (PRTK)?
PARATEK PHARMACEUTICALS INC (PRTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.1).
PRTK Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PRTK. When comparing the yearly performance of all stocks, PRTK turns out to be only a medium performer in the overall market: it outperformed 48.22% of all stocks.
PRTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRTK. Both the profitability and financial health of PRTK have multiple concerns.
PRTK Financial Highlights
Over the last trailing twelve months PRTK reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 35.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PRTK Forecast & Estimates
9 analysts have analysed PRTK and the average price target is 3.16 USD. This implies a price increase of 41.79% is expected in the next year compared to the current price of 2.23.
For the next year, analysts expect an EPS growth of 32.14% and a revenue growth 9.93% for PRTK